Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG daily Stock Chart
Novartis AG
Index- P/E28.68 EPS (ttm)2.77 Insider Own9.30% Shs Outstand2.64B Perf Week-2.50%
Market Cap209.02B Forward P/E15.65 EPS next Y5.07 Insider Trans0.24% Shs Float2.53B Perf Month-3.37%
Income6.67B PEG4.66 EPS next Q1.19 Inst Own10.10% Short Float0.17% Perf Quarter-1.00%
Sales49.78B P/S4.20 EPS this Y-33.30% Inst Trans-1.19% Short Ratio2.86 Perf Half Y11.53%
Book/sh30.43 P/B2.61 EPS next Y7.12% ROA5.10% Target Price93.25 Perf Year-16.46%
Cash/sh- P/C- EPS next 5Y6.16% ROE9.10% 52W Range68.87 - 95.26 Perf YTD-4.23%
Dividend2.72 P/FCF105.41 EPS past 5Y-7.50% ROI7.80% 52W High-16.74% Beta0.57
Dividend %3.43% Quick Ratio0.60 Sales past 5Y-0.50% Gross Margin65.00% 52W Low15.16% ATR1.01
Employees118000 Current Ratio0.90 Sales Q/Q-1.70% Oper. Margin16.90% RSI (14)30.32 Volatility1.77% 1.02%
OptionableYes Debt/Eq0.36 EPS Q/Q-0.80% Profit Margin13.60% Rel Volume0.99 Prev Close79.55
ShortableYes LT Debt/Eq0.22 EarningsJul 19 BMO Payout94.00% Avg Volume1.48M Price79.31
Recom2.40 SMA20-3.37% SMA50-2.73% SMA2001.32% Volume1,468,856 Change-0.30%
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-06-07Initiated UBS Buy
Aug-26-16 06:18PM  Can Novartis Tide Over the Alcon Crisis?
04:03PM  Novartis AG (NVS) Announces Positive Phase III Results For MS Drug at Insider Monkey
10:20AM  Novartis (NVS) Reports Positive Phase III Results on MS Drug
Aug-25-16 11:04AM  AbbVie Expects to Launch Zinbryta in the US in August
Aug-24-16 04:49PM  Why Momenta Pharmaceuticals Shares Made a Late-Day Jump Higher at Motley Fool
03:30PM  Waiting For Growth, Or A Better Valuation, Argus Stays Sidelined On Novartis Shares
11:04AM  Imbruvica Continues to Report Better-than-Expected Sales in 2016
08:50AM  Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics
Aug-23-16 07:04PM  Performance of AstraZenecas Growth Platforms in 2Q16
05:04PM  Why AstraZeneca Reported Negative Growth in 2Q16
11:11AM  Top 6 Pharmaceutical Companies Globally at Investopedia
11:00AM  Cyon Therapeutics Inc. acquires world-wide rights to an anti-PCSK9 antibody for use in Severe Infection and Sepsis CNW Group
Aug-22-16 11:04AM  How Merial Contributes to Sanofis Growth
Aug-21-16 11:41AM  3 Reasons Medivation Is the Juiciest Target in Biotech at Motley Fool
Aug-19-16 01:19PM  Novartis: First-Class Pharmaceuticals
11:04AM  What Happened to Sanofis Consumer Healthcare and Generics Franchise in 2Q16?
Aug-18-16 01:30PM  5 Stocks That Beat The Market In A Crash
09:06AM  Genzyme Continued to Boost Growth for Sanofi in 2Q16
09:04AM  Ozanimod May Prove to Be a Strong Growth Driver for Celgene
Aug-17-16 11:04AM  CELGs Otezla Continues Dominating US Inflammation and Immunology
08:21AM  Better Buy: Amgen Inc. vs. Biogen at Motley Fool
08:13AM  With new president and focus on big investors, Cellceutix aims for the Nasdaq at
02:54AM  CSL to hike spending after profit fall AAP
Aug-16-16 09:23PM  CSL to raise $US500m after mixed results AAP
06:48PM  Novartis Needs to Stem the Bleeding From Gleevec Decline
09:05AM  Valeant: Are the Salix and Dermatology Portfolios Recovering?
Aug-15-16 09:13AM  Allergan to Buy ForSight VISION5, Boost Glaucoma Pipeline
Aug-13-16 06:22AM  Novartis Korea executives charged with bribing doctors
12:01AM  [$$] 5 Safe European Stocks With Yields Up to 5% at
Aug-12-16 10:00AM  Who Is Driving Novarti's Management Team? (NVS, BAYRY) at Investopedia
Aug-11-16 11:04AM  Pfizers Products with Decreasing Revenues
10:00AM  Novartis Upends Early-Stage Drug Research at Forbes
06:19AM  [$$] Novartis faces potential South Korea sales ban at Financial Times
02:48AM  Novartis could face S.Korea sales ban amid corruption allegations: media AFP
Aug-10-16 04:41PM  Lilly Breast Cancer Drug Study Rolls On, Pushing Back Launch Date
Aug-09-16 01:55PM  ETFs with exposure to Novartis AG : August 9, 2016
Aug-08-16 04:59PM  Canada's Plan To Fight Opioid Addiction Might Hurt Its Weakest Patients
11:53AM  How Will Novartis (NVS) Stock React to Asthma Pill Trial Success?
07:15AM  Despite trial setback, Momenta shares surge on generics news and buyout rumors at
Aug-05-16 10:20AM  Jefferies Keeps Red-Hot Dividend Pharmaceutical Stock as Top Sector Pick at 24/7 Wall St.
Aug-03-16 05:13PM  Generics Keeping The Pressure On Big Pharma
03:05PM  Can Novartis Win the Entresto Bet?
09:05AM  GlaxoSmithKlines Consumer Healthcare Grows in 2Q16
01:30AM  Novartis pill gets U.S. breakthrough designation in breast cancer Reuters
Aug-02-16 09:36AM  CVS Cuts Coverage of Dozens of Drugs in Exclusion Expansion at Bloomberg
Aug-01-16 09:09AM  These Drugs Were Key Growth Drivers for Amgens Revenue in 2Q16
08:25AM  Donald Trump And Drug Companies at Forbes
Jul-29-16 01:57PM  Amgens Bone Health Drug Saw Strong Revenue Growth in 2Q16
01:57PM  Growth Products Drove Amgens Revenue Performance in 2Q16
01:44PM  ETFs with exposure to Novartis AG : July 29, 2016
01:40PM  Amgen Continued to Manage Life Cycles of Its Mature Brands in Q2
Jul-28-16 02:13PM  AstraZeneca (AZN) Stock Up After Q2 Earnings, Revenue Beat
08:34AM  AstraZeneca a bid target again? CEO says someone may spot value
05:43AM  AstraZeneca a takeover target again? CEO not commenting
Jul-27-16 11:04AM  Analyst Recommendations for Roche: Buy, Hold, or Sell?
09:09AM  BIIB Continues to Lead the MS Treatment Market in the US in 2016
Jul-26-16 10:15AM  Novartis AG :NVS-US: Earnings Analysis: Q2, 2016 By the Numbers : July 26, 2016
09:04AM  Newly Acquired Products Boost GlaxoSmithKlines Earnings
09:04AM  What Do the Recent Changes in Novartiss 2Q16 Valuation Tell Us?
08:21AM  An Investing Overview of the Multiple Sclerosis Market at Motley Fool
Jul-25-16 11:04AM  How Do the Majority of Analysts Rate Novartis after 2Q16?
09:07AM  Sales Performance Analysis of Roches Pharmaceuticals Division
09:07AM  GSK 2Q16 Earnings: Did Pharmaceuticals Grow?
08:49AM  Glaxo (GSK) Q2 Earnings: Can the Stock Pull a Surprise?
Jul-22-16 04:11PM  Eli Lilly, J&J, Novo Battle Diabetes -- And Each Other
03:39PM  GlaxoSmithKline Segments That Drive Companys Rising Revenues
01:15PM  What Role Did Innovative Medicines Play in Novartiss 2Q16 Earnings?
01:07PM  What Are Lillys 2Q16 Estimates and Expectations for Elanco?
Jul-21-16 02:01PM  Research Reports on Facebook (FB), Tesla (TSLA) & Others Zacks
01:49PM  Inside the Foreign Exchange Impact on Novartiss Growth in 2Q16
01:49PM  How Did Novartiss 2Q16 Earnings Stand up to Analyst Estimates?
08:40AM  Opioid Addiction: What To Do When A Loved One Is Hooked, According To Science
02:20AM  Roche Beats First-Half Forecasts as Cancer Drug Sales Rise
Jul-20-16 10:15AM  Novartis (NVS) Tops Q2 Earnings & Sales, Expenses to Grow
09:44AM  These new drugs might never get a chance to save the U.S. $250 billion at MarketWatch
Jul-19-16 07:00PM  Pricing dispute hits supply of TB drugs in Pakistan Reuters
05:30PM  Amgen Finally Scores a Win in Its Big Copycat Drug Battle With Novartis at Fortune
04:47PM  Novartis Shares Slip Tuesday on Falling Profit at TheStreet
04:35PM  What Lilly Expects for Revenue Growth in 2Q16
01:41PM  Novartis Set To Become Biosimilar Pioneer By 2020
01:07PM  Novartis Set To Become Biosimilar Pioneer By 2020 at Forbes
12:55PM  ETFs with exposure to Novartis AG : July 19, 2016
10:06AM  Medical Stocks to Post Earnings This Week: ABT, BIIB, ALIOF
09:59AM  Novartis profit slips as generic drug competition hits sales
09:11AM  [$$] Novartis braced for US price shake-up after presidential election at Financial Times
08:55AM  Novartis (NVS) Stock Down on Profit Warning
08:42AM  U.S. FDA knocks back Novartis copy of Amgen's drug Neulasta Reuters
07:58AM  Early movers: GS, UNH, JNJ, NFLX, PM, CMG, IBM, YHOO, AMZN & more at CNBC
06:05AM  Novartis beats 2Q profit forecasts
05:35AM  Novartis Ramps Up Heart Drug Spending as Top Seller Goes Generic at Bloomberg
04:07AM  [$$] Novartis Warns on Profit at The Wall Street Journal
03:43AM  Novartis, world's top drugmaker, plays down Brexit threat Reuters
03:16AM  Novartis warns 2016 profit may fall on higher heart drug spending
02:22AM  Novartis Second-Quarter Earnings, Revenue Fall Less Than Forecast
02:07AM  Novartis (NVS) Beats Earnings & Sales in Q2
01:05AM  Novartis Says Profit May Drop on Entresto Spending, Gleevec at Bloomberg
Jul-18-16 11:07AM  How Much Potential Does Promacta Hold?
10:12AM  Why Earnings Season Could Be Great for Novartis AG (NVS)
09:45AM  Why Novartiss 2Q16 Revenues Are Expected to Fall
09:45AM  Novartiss 2Q16 Earnings: Whats Expected?
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The company has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and with Caribou Biosciences for the development of drug discovery tools. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Institutes for BioMed10% OwnerMay 11Buy18.00277,7774,999,9865,573,658May 11 06:57 PM
Novartis Bioventures Ltd10% OwnerApr 12Buy10.00300,0003,000,0002,310,924Apr 12 05:09 PM
Novartis Bioventures Ltd10% OwnerFeb 17Buy8.00375,0003,000,0001,873,791Feb 17 06:47 PM